

10 February 2026

LAUNCH OF LIBBO AND ACTIVATION OF MEN'S HEALTH PLATFORM

- Commercial launch of Libbo™, EVE's oral dissolving film treatment for erectile dysfunction, now underway in Australia
- Dedicated men's health digital education platform, www.stiffissue.com, now live
- Telehealth prescribing and pharmacy fulfilment operational through hubMed, TeleDocs Clinic and Chemist2U
- Establishment of an end-to-end digital assessment, prescribing and delivery pathway
- Marks transition from manufacturing and distribution into real-world patient access, supporting scalable national access and near-term revenue generation

EVE Health Group (ASX:EVE, EVE or the Company) an Australian life sciences company is pleased to announce the commercial launch of Libbo™ in Australia, alongside the activation of its integrated digital marketing, medical education, prescribing, and fulfilment platform for men's health.

This milestone follows the successful completion of Libbo™ manufacturing and delivery of inventory into national distribution, as previously announced, and represents the next step in EVE's progression from development and supply readiness into real-world patient access.

The launch includes the go-live of Eve's dedicated online platform, www.stiffissue.com, together with established telehealth prescribing partnerships with HubMed and TeleDocs Clinic, and prescription fulfilment through Chemist2U. This integrated ecosystem enables eligible patients to access assessment, consultation, prescription, and delivery through a streamlined digital pathway.

Patient Access Platform and Access Pathway

The stiffissue.com platform has been developed to provide a centralised digital gateway for men seeking discreet, convenient, and clinically supported access to erectile dysfunction treatment.

In addition to facilitating access to medical consultation and prescription services, the platform provides education and support resources designed to help normalise erectile dysfunction as a common and readily treatable medical condition. These resources aim to reduce stigma, address misconceptions, and encourage earlier engagement with appropriate care.

The platform incorporates patient education, digital onboarding, and clinical assessment, with referrals to independent telehealth providers hubMed and TeleDocs Clinic for medical consultation. Where clinically appropriate, prescriptions are issued and fulfilled through Chemist2U, enabling direct-to-patient delivery.

This integrated model establishes an end-to-end digital pathway encompassing assessment, consultation, prescribing, and fulfilment, and is designed to support responsible prescribing, patient engagement, and scalable national access within a regulated healthcare framework.

Commercial and Strategic Context

Libbo™ is being commercialised through established telehealth prescribing pathways and pharmacy fulfilment partners, leveraging authorised prescriber frameworks and national distribution infrastructure already in place.

By combining proprietary pharmaceutical products with digital engagement and clinical networks, EVE is executing a vertically integrated commercial model intended to accelerate market entry, support patient access and build sustainable revenue streams in men's health.

The activation of the digital platform also provides a foundation for future product extensions and expansion into additional therapeutic indications.

Addressing Patient Access and Treatment Barriers

Erectile dysfunction is a common and often under treated condition, affecting approximately one in five adult men and up to 40 percent of men over the age of 40. Despite the availability of effective therapies, many men delay seeking treatment due to stigma, inconvenience and concerns regarding privacy.

A key barrier to treatment remains limited understanding that erectile dysfunction is frequently linked to underlying health factors and is, in most cases, readily treatable with appropriate medical support. Traditional healthcare pathways can present both practical and psychological barriers, contributing to reduced engagement and suboptimal outcomes.

Through the launch of its integrated digital platform, EVE aims to reduce these barriers by providing a discreet, convenient, and clinically supported pathway to assessment and treatment, aligned with the Company's broader strategy to improve access to evidence-based care in underserved health areas.

EVE Chief Executive Officer, Damian Wood, said: "The commencement of Libbo's commercial launch represents a key milestone in EVE's transition from manufacturing and distribution into real-world patient access.

With the stiffissue.com digital platform now live and prescribing and fulfilment pathways operational, we have established the core infrastructure required to support scalable national access in men's health.

This milestone reflects the disciplined execution of our commercial strategy and positions the Company to build a meaningful and sustainable presence in the men's health sector."

Authorised for release by the Board of Directors.

Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The company's lead assets include Dyspro, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

For personal use only